Salemonline Journal

Richter’s Syndrome Pipeline Insight 2021 by DelveInsight

 Breaking News
  • No posts were found

Richter’s Syndrome Pipeline Insight 2021 by DelveInsight

August 09
19:56 2021
Richter’s Syndrome Pipeline Insight 2021 by DelveInsight

DelveInsight’s Richter’s Syndrome Pipeline Insight, 2021 report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Richter’s Syndrome pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.


Richter’s Syndrome Overview

Richter’s Syndrome (RS), also known as Richter’s Transformation, is a rare complication of Chronic Lymphocytic Leukaemia (CLL) and/or Small Lymphocytic Lymphoma (SLL). It is characterised by the sudden transformation of the CLL/SLL into a significantly more aggressive form of large cell lymphoma. Richter’s Syndrome occurs in approximately 2-10% of all CLL/SLL patients during the course of their disease.


Approach to free sample copy-


List of regions covered in the report

  • Global


List of companies involved in the report

  • TG Therapeutics
  • Secura Bio
  • AstraZeneca
  • Vincerx Pharma
  • Merck & Co
  • And many others


Richter’s Syndrome Symptoms

The most common symptoms of Richter’s Syndrome arise from a sudden and dramatic increase in the size of lymph nodes (also known as ‘lymphadenopathy’) characterised by usually painless areas of swelling in the neck, axilla, abdomen (most commonly in the spleen, also known as ‘splenomegaly’) or groin. Patients also often experience a dramatic increase in unexplained weight loss, fevers and night sweats (often collectively referred to as ‘B-symptoms’).


Richter’s Syndrome Diagnosis

The definitive or differential diagnosis of Richter’s Syndrome is achieved by an excisional biopsy or CT/ultrasound guided core needle biopsy of an enlarged lymph node that is thought to be indicative of the Richter’s transformation. The current standard first-line treatment for this type of lymphoma is the immuno-chemotherapy using a combination of chemo drugs and a targeted anti-CD 20 monoclonal antibody. Other second-line chemotherapy regimens often used to treat this type of lymphoma (if non-responsive or ‘refractory’ to R-CHOP) include R-ICE, D-HAC, R-DHAP, GIVE, etc.


Richter’s Syndrome Emerging Drugs

Duvelisib: Secura Bio

Duvelisib, is a small-molecule inhibitor of phosphoinositide-3 kinases that was designed initially to prove that simultaneous inhibition of the isoforms delta and gamma can produce a broad adaptative and innate immune cell inhibitory activity. It is currently in Phase II stage of development for the treatment of Richter’s Syndrome and is being developed by Secura Bio.


Richter’s Syndrome Phases

  • Late-stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage products (Phase I/II and Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration


Approach to free sample copy-


Table of content

  • Introduction
  • Executive Summary
  • Richter’s Syndrome: Overview
  • Pipeline Therapeutics
  • Therapeutic Assessment
  • Richter’s Syndrome– DelveInsight’s Analytical Perspective
  • In-depth Commercial Assessment
  • Richter’s Syndrome Collaboration Deals
  • Late Stage Products (Phase III)
  • Drug Name: Company Name
  • Mid Stage Products (Phase II)
  • Duvelisib: Secura Bio
  • Early Stage Products (Phase I)
  • AZD4573: AstraZeneca
  • Preclinical and Discovery Stage Products
  • Drug Name: Company Name
  • Inactive Products
  • Richter’s Syndrome Key Companies
  • Richter’s Syndrome Key Products
  • Richter’s Syndrome- Unmet Needs
  • Richter’s Syndrome- Market Drivers and Barriers
  • Richter’s Syndrome- Future Perspectives and Conclusion
  • Richter’s Syndrome Analyst Views
  • Richter’s Syndrome Key Companies
  • Appendix


Richter’s Syndrome Report Insights

  • Richter’s Syndrome Pipeline Analysis
  • Therapeutic Assessment
  • Unmet Needs
  • Impact of Drugs


Richter’s Syndrome Report Assessment

  • Pipeline Product Profiles
  • Therapeutic Assessment
  • Pipeline Assessment
  • Inactive drugs assessment
  • Unmet Needs


Key Questions

Current Scenario and Emerging Therapies:

  • How many companies are developing Richter’s Syndrome drugs?
  • How many Richter’s Syndrome drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for Richter’s Syndrome?
  • What are the key collaborations (Industry–Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Richter’s Syndrome therapeutics?
  • What are the recent trends, drug types, and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Richter’s Syndrome and their status?
  • What are the key designations that have been granted to the emerging drugs?


About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for life science vertical and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States

Related Articles